President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland could disrupt one export that is wildly popular in America:

For Novo Nordisk, a company still rooted in principles ... This is particularly the case in developing nations, from Mexico to the Gulf States, China and India, where healthcare systems are ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a

TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the

Mads Krogsgaard Thomsen, CEO of Novo Nordisk Foundation, discusses European competitiveness.

European markets were subdued on Tuesday, with the STOXX 600 up 0.1 percent as healthcare and financials gains offset losses in automakers and renewable energy. Trump’s delay on new tariffs offered relief,

(Reuters) -European shares rose on Tuesday, buoyed by gains in the healthcare and luxury sectors, but the uptick was tempered by lingering uncertainties over U.S. President Donald Trump's proposed tariff measures following his inauguration.

(Reuters) - European shares were subdued on Tuesday, as rising financials and healthcare shares countered broader losses stemming from uncertainty related to U.S. President Donald Trump's proposed tariff measures following his inauguration. The pan-European STOXX 600 was up 0.1% as of 0954 GMT, hovering near its highest in three months.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

European equities rose on Tuesday on relief that US President Donald Trump had refrained from immediately targeting the region with trade tariffs.

European shares held steady with slight gains in financials and healthcare despite global uncertainties over U.S. President Donald Trump's proposed tariffs. The market's cautious optimism was challenged by pressure on automakers and basic resources.